Get the Stockscreener App
1.75
1.13%
-0.02
After Hours:
1.75
Zentalis Pharmaceuticals Inc stock is traded at $1.75, with a volume of 422.71K.
It is down -1.13% in the last 24 hours and up +24.11% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.77
Open:
$1.77
24h Volume:
422.71K
Relative Volume:
0.44
Market Cap:
$126.24M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3855
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+3.55%
1M Performance:
+24.11%
6M Performance:
-9.33%
1Y Performance:
-45.99%
1-Day Range:
$1.71
$1.79
1-Week Range:
$1.60
$1.82
52-Week Range:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.75 | 127.68M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Understanding Zentalis Pharmaceuticals Inc.’s price movement2025 Market Outlook & Smart Swing Trading Alerts - Newser
How to use Fibonacci retracement on Zentalis Pharmaceuticals Inc.2025 Biggest Moves & AI Driven Stock Reports - Newser
Zentalis Pharmaceuticals Inc. stock momentum explainedJuly 2025 Fed Impact & Verified Momentum Watchlists - Newser
Aug PreEarnings: Is Zentalis Pharmaceuticals Inc. stock trending bullishJuly 2025 Update & Weekly High Return Opportunities - خودرو بانک
Is Zentalis Pharmaceuticals Inc. stock showing strong momentumFed Meeting & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Will Zentalis Pharmaceuticals Inc. outperform during market ralliesInsider Buying & Momentum Based Trading Signals - خودرو بانک
Will Zentalis Pharmaceuticals Inc. benefit from AI trendsWeekly Trend Summary & Daily Technical Forecast Reports - خودرو بانک
What is the next catalyst for Zentalis Pharmaceuticals Inc.Trade Risk Summary & Verified Momentum Watchlists - خودرو بانک
Published on: 2025-09-05 14:44:43 - Newser
Applying Elliott Wave Theory to Zentalis Pharmaceuticals Inc.2025 Year in Review & Stepwise Trade Signal Guides - Newser
Breakouts Watch: Is Zentalis Pharmaceuticals Inc. stock showing strong momentumQuarterly Profit Report & Accurate Buy Signal Notifications - خودرو بانک
Is a relief rally coming for Zentalis Pharmaceuticals Inc. holdersJuly 2025 Drop Watch & Safe Entry Point Identification - Newser
Zentalis Pharmaceuticals Inc. stock outlook for YEARJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Using Ichimoku Cloud for Zentalis Pharmaceuticals Inc. technicalsRate Cut & High Conviction Buy Zone Picks - Newser
Published on: 2025-09-04 22:09:09 - Newser
Why Zentalis Pharmaceuticals Inc. is moving today2025 Big Picture & Fast Gaining Stock Reports - Newser
Using portfolio simulators with Zentalis Pharmaceuticals Inc. includedEarnings Overview Report & Expert Approved Momentum Ideas - Newser
Chart Patterns Forming a Bullish Setup in Zentalis Pharmaceuticals Inc.2025 Trading Volume Trends & Advanced Technical Analysis Signals - beatles.ru
Is Zentalis Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Using data tools to time your Zentalis Pharmaceuticals Inc. exitWeekly Stock Report & High Accuracy Swing Entry Alerts - Newser
Visualizing Zentalis Pharmaceuticals Inc. stock with heatmapsEarnings Growth Report & Safe Capital Growth Plans - Newser
Will Zentalis Pharmaceuticals Inc. outperform the market2025 Market Sentiment & Weekly High Return Opportunities - Newser
Published on: 2025-09-04 07:20:30 - خودرو بانک
Is Zentalis Pharmaceuticals Inc. stock trending bullishMarket Rally & Real-Time Volume Trigger Notifications - خودرو بانک
Using R and stats models for Zentalis Pharmaceuticals Inc. forecastingEarnings Beat & AI Enhanced Trading Alerts - Newser
Zentalis Pharmaceuticals shares fall 1.45% intraday after announcing inducement grants to new employees. - AInvest
Will Zentalis Pharmaceuticals Inc. stock recover after earningsJuly 2025 Breakouts & Risk Managed Investment Strategies - خودرو بانک
Published on: 2025-09-03 05:20:27 - Newser
Will Zentalis Pharmaceuticals Inc. outperform small cap indexesWeekly Profit Analysis & Safe Capital Growth Tips - خودرو بانک
Is Zentalis Pharmaceuticals Inc. impacted by rising ratesCEO Change & Safe Investment Capital Preservation Plans - خودرو بانک
Heatmap analysis for Zentalis Pharmaceuticals Inc. and competitorsBuy Signal & Real-Time Volume Surge Alerts - Newser
Advanced analytics toolkit walkthrough for Zentalis Pharmaceuticals Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Can Zentalis Pharmaceuticals Inc. deliver consistent EPS growth2025 Trading Volume Trends & Long-Term Capital Growth Strategies - خودرو بانک
Tools to monitor Zentalis Pharmaceuticals Inc. recovery probabilityBuy Signal & Accurate Buy Signal Notifications - Newser
Zentalis Pharmaceuticals announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Zentalis Pharmaceuticals Grants Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
381,000 Shares: Zentalis Pharmaceuticals Awards Major Stock Options Package to New Executive Hires - Stock Titan
Is Zentalis Pharmaceuticals Inc. forming a bullish divergenceWeekly Trade Report & Free Expert Verified Stock Movement Alerts - خودرو بانک
What are the risks of holding Zentalis Pharmaceuticals Inc.Earnings Beat & Long-Term Growth Plans - خودرو بانک
Can Zentalis Pharmaceuticals Inc. weather a recessionJuly 2025 Levels & Community Driven Trade Alerts - خودرو بانک
Can volume confirm reversal in Zentalis Pharmaceuticals Inc.Market Risk Summary & Proven Capital Preservation Methods - Newser
Long term hold vs stop loss in Zentalis Pharmaceuticals Inc.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):